As a MET kinase inhibitor, PLB-1001 had remarkable potency in selectively inhibiting MET-altered tumor cells in preclinical models and clinically achieved partial response in some advanced secondary GBM patients (NCT02978261) (50). This evidence concerns the gene MET and glioblastoma.